Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2019-06-25 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于召开2019年第三次临时股东大会通知的公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2019 third extraordinary general meeting (临时股东大会) of Shenzhen Haier Bioengineering Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures, and proxy authorization. The content focuses on shareholder meeting logistics and proposals to be voted on, including non-public stock issuance plans and related corporate governance matters. There are no financial statements or detailed financial performance data presented, nor is this a transcript or a report of voting results. The document is not a report itself but an announcement and notice for a shareholder meeting with detailed agenda and voting instructions. Therefore, it fits best into the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2019-06-25 Chinese
2019年度非公开发行股票预案
Capital/Financing Update Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司 2019 年度非公开发行股票预案," which translates to "Shenzhen Neptunus Bioengineering Co., Ltd. 2019 Non-public Issuance of Shares Proposal." The content discusses a non-public issuance of A shares, including details about the issuance plan, background, purpose, pricing, issuance objects, and regulatory approvals. It includes detailed financial and strategic information related to the capital raising activity. This is clearly an update on the company's capital raising and financing activities rather than a full annual report, earnings release, or other types of filings. The document is comprehensive and not a brief announcement or a report publication notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-06-25 Chinese
中国银河证券股份有限公司关于公司非公开发行限售股份解除限售的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from China Galaxy Securities regarding the lifting of restrictions on non-publicly issued shares of Shenzhen Haier Bioengineering Co., Ltd. It details the background of the share issuance, the shareholders' commitments, the unlocking date, and the shareholding structure before and after the unlocking. The document is a verification and opinion letter from the sponsor institution about the share unlocking event, not a financial report or earnings release. It does not contain financial statements or earnings data but focuses on regulatory compliance and share circulation matters. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and verification announcement related to share unlocking and does not fit other more specific categories like Capital/Financing Update or Share Issue/Capital Change, which usually announce new issuances or capital changes rather than unlocking of restricted shares.
2019-06-20 Chinese
关于非公开发行限售股份解除限售的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the lifting of restrictions on non-publicly issued restricted shares. It details the number of shares becoming tradable, the shareholder involved, the dates, and compliance with regulatory requirements. The document is an announcement about share unlocking and circulation, not a financial report or detailed analysis. It does not contain financial statements or management discussion but focuses on share capital changes and regulatory compliance related to share restrictions. The document length is 2831 characters, relatively short, and it serves as a formal notification of share restriction removal. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as lifting share restrictions.
2019-06-20 Chinese
2017年面向合格投资者公开发行公司债券（第一期）2019年付息公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment for a corporate bond issued by Shenzhen Haier Bioengineering Co., Ltd. It details the bond's interest payment date, interest rate, bondholder eligibility, tax information, and related procedural details. The document does not contain financial statements or comprehensive financial data but rather provides information about the bond interest payment event. It is a formal notice to investors about the bond coupon payment, which fits the category of Capital/Financing Update (CAP) as it relates to the company's debt financing activities and interest payments. The document length is 3521 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2019-06-18 Chinese
关于举办投资者交流会活动的公告
Investor Presentation Classification · 95% confidence The document is a public announcement from Shenzhen Haiwang Bioengineering Co., Ltd. about organizing an investor communication meeting scheduled for June 14, 2019. It includes details such as time, location, participating senior management, and instructions for investors to register. The document does not contain any financial data, report content, or voting results. It is an announcement of an event aimed at investor relations rather than a report or transcript. Therefore, it fits best under the category of Investor Presentation (IP), as it relates to a presentation or meeting for investors focusing on company information and engagement.
2019-06-12 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.